Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SPRC
stocks logo

SPRC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Scisparc Ltd (SPRC.O) is 0.00, compared to its 5-year average forward P/E of -11.57. For a more detailed relative valuation and DCF analysis to assess Scisparc Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.57
Current PE
0.00
Overvalued PE
26.16
Undervalued PE
-49.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.45
Current PS
0.00
Overvalued PS
4.52
Undervalued PS
-1.63
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SPRC News & Events

Events Timeline

(ET)
2025-12-02
09:40:00
SciSparc Acquires 55% Stake in NeuroThera from Quantum Bio Data Firm
select
2025-12-01 (ET)
2025-12-01
08:50:00
SciSparc Acquires 19.99% Stake in Xylo's Patent Portfolio for Innovative Medical Systems
select
2025-11-26 (ET)
2025-11-26
07:45:31
SciSparc to Obtain Patent Portfolio for Medical Endoscopy Technologies
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-02Newsfilter
PinnedSciSparc Acquires 55% Stake in NeuroThera for 40% Equity
  • Acquisition Agreement: SciSparc's majority-owned NeuroThera Labs has entered a non-binding term sheet to acquire a 55% stake in a pioneering Israeli quantum computing bio data company in exchange for 40% of NeuroThera's equity, indicating a strategic move into quantum computing.
  • Innovative Technology Potential: By leveraging quantum computing, NeuroThera aims to enhance the efficiency of bio data storage and analysis, potentially revolutionizing clinical trials and accelerating drug development processes while improving precision in medical research.
  • Complex Transaction Conditions: The acquisition is subject to due diligence, negotiation, execution of definitive agreements, and obtaining all necessary corporate and regulatory approvals, highlighting the complexity and uncertainty of the deal.
  • Broad Market Prospects: Through this acquisition, SciSparc not only strengthens its competitive position in treating central nervous system disorders but also potentially drives innovation in the healthcare sector via quantum intelligence technology, opening new market opportunities.
[object Object]
Preview
8.5
11-26Benzinga
Reasons Behind Today's Increase in SciSparc Stock

  • Strategic Acquisition: SciSparc Ltd. is acquiring endoscopy intellectual property from Xylo Technologies, marking a shift from its neuroscience focus to medical device commercialization, specifically targeting gastroesophageal reflux disease (GERD) with the MUSE platform.

  • Commercialization Plans: The MUSE device, designed for minimally invasive procedures, aims to leverage Xylo's past success in Greater China to expand into North America, Europe, and Latin America through exclusive regional partnerships.

  • Equity Structure: As part of the acquisition, SciSparc will issue equity representing 19.99% of its outstanding shares, potentially substituting some with pre-funded warrants, granting it direct ownership and commercialization rights.

  • Market Response: Following the announcement, SciSparc's stock rose by 29.10% to $3.15, approaching its 52-week low of $1.75, indicating positive market sentiment regarding the acquisition.

[object Object]
Preview
7.5
11-26Newsfilter
SciSparc Acquires MUSE™ Endoscopic Patent Portfolio to Expand Global Market Reach
  • Patent Acquisition: SciSparc has signed a binding term sheet to acquire the patents and trademarks for the MUSE™ endoscopic system from Xylo, which is expected to significantly enhance its competitive position in the gastroesophageal reflux disease (GERD) treatment market.
  • Market Expansion Strategy: SciSparc plans to replicate Xylo's successful commercialization model in Greater China across high-growth territories such as North America, Europe, and Latin America by establishing exclusive partnerships with leading regional distributors to accelerate global commercialization.
  • Financial Impact: As part of the acquisition, SciSparc will issue ordinary shares representing 19.99% of its issued share capital to Xylo, which is anticipated to create new revenue streams for SciSparc and further drive company growth.
  • Market Outlook: According to a market research report, the global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, growing at a CAGR of 3.24%, providing substantial market opportunities for SciSparc.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Scisparc Ltd (SPRC) stock price today?

The current price of SPRC is 1.77 USD — it has increased 3.51 % in the last trading day.

arrow icon

What is Scisparc Ltd (SPRC)'s business?

Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

arrow icon

What is the price predicton of SPRC Stock?

Wall Street analysts forecast SPRC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Scisparc Ltd (SPRC)'s revenue for the last quarter?

Scisparc Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Scisparc Ltd (SPRC)'s earnings per share (EPS) for the last quarter?

Scisparc Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Scisparc Ltd (SPRC)'s fundamentals?

The market is revising No Change the revenue expectations for SPRC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -20.63%.
arrow icon

How many employees does Scisparc Ltd (SPRC). have?

Scisparc Ltd (SPRC) has 2 emplpoyees as of December 05 2025.

arrow icon

What is Scisparc Ltd (SPRC) market cap?

Today SPRC has the market capitalization of 5.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free